Multiple sclerosis (MS) is considered an immune disease of the central nervous system, and the most important effective therapies are based on drugs which are able to modify the systemic immune system (immunomodulating and immunosuppressant agents)

Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial

D’Amico, Emanuele
Conceptualization
;
2017

Abstract

Multiple sclerosis (MS) is considered an immune disease of the central nervous system, and the most important effective therapies are based on drugs which are able to modify the systemic immune system (immunomodulating and immunosuppressant agents)
Alemtuzumab; Autologous hematopoietic stem cell transplantation; Monoclonal antibodies; Multiple sclerosis; Second-line treatment; Molecular Medicine; Genetics; Pharmacology; Drug Discovery3003 Pharmaceutical Science
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/360518
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact